Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
A recently published study sparks hope that the world is getting closer to developing a cure for the human immunodeficiency virus (HIV). Scientists reported finding the kill switch to dormant reservoirs of the virus in a patient’s body.
HIV cure: Elimination of virus is possible, study shows
Much like cancer, HIV infection remains one of the most difficult medical science challenges today because experts have yet to develop a cure that would eliminate it from the body. On the bright side, decades of study have resulted in the development of antiretroviral therapy that practically keeps HIV at bay. ART is usually administered through a pill that patients need to take daily.
ART drugs make HIV inactive and remain in reservoirs in a patient’s body. So when the patient stops taking their ART medication, the virus is reactivated and often causes more serious damage to the body.
This characteristic of HIV is what makes the research by scientists from the University of California, San Diego (UCSD) School of Medicine so important. The study, published in mBio, reports finding a switch that helps in the spread of HIV in the body after conducting the first-ever genome-wide expression analysis of long noncoding RNA (lncRNA) in HIV-infected macrophages.
Simply put, lncRNAs are responsible for regulating genes in the cells that means these also act as an on-and-off switch. The experiment led scientists to identify the HIV-1 Enhanced LncRNA (HEAL) that is now regarded as the key to further understanding how HIV replicates even in immune cells and how to stop it from doing so. The research is a proof of the concept that HEAL plays a key role in preventing HIV from being reactivated even after a patient stops taking ART drugs.
Is it possible to cure HIV?
Almost 38 million people are living with HIV all over the world per the report of UNAIDS, and around 1.7 million of those were newly recorded cases. This means that despite the availability of ART and pre-exposure prophylaxis (PrEP) drugs against HIV, it remains one of the biggest health crises globally.
However, not all hope is lost. The research mentioned above is not the only one that has proven there is a way to kill HIV. It is only a matter of time for scientists to use these breakthroughs in developing a complete cure.
